David Miller
Private Equity Investor chez Alpine Bioventures, GP, LLC
Profil
David Miller is the founder of Biotech Stock Research LLC, which was founded in 1999.
He held the title of President & Chief Executive Officer from 2001 to 2012.
Mr. Miller is currently the Senior Director of Strategic Communications at Curevo, Inc. since 2023 and the Principal at Alpine Bioventures, GP, LLC since 2013.
He previously worked as the Director of Corporate Affairs at Angion Biomedica Corp.
and as the Director of Communications at Alpine Immune Sciences, Inc. from 2015 to 2019.
Mr. Miller obtained his undergraduate degree from Western Washington University in 1990.
Postes actifs de David Miller
| Sociétés | Poste | Début |
|---|---|---|
Alpine Bioventures, GP, LLC
 Alpine Bioventures, GP, LLC Investment ManagersFinance Alpine Bioventures, GP, LLC (Alpine Bioventures) is a venture capital firm founded by Mitchell H. Gold in 2013. The firm is headquartered in Seattle, Washington. | Private Equity Investor | 01/09/2013 |
Curevo, Inc.
 Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | Corporate Officer/Principal | 01/04/2023 |
Anciens postes connus de David Miller
| Sociétés | Poste | Fin |
|---|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Private Equity Investor | 01/05/2019 |
| ANGN BIOM | Corporate Officer/Principal | - |
Biotech Stock Research LLC
 Biotech Stock Research LLC Investment ManagersFinance Founded in 1999, Biotech Stock Research LLC, the parent of Biotech Monthly, is a research firm headquartered in Seattle, Washington. The firm conducts primary and secondary research on developmental-stage biotechnology companies. | Founder | - |
Formation de David Miller
| Western Washington University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Biotech Stock Research LLC
Biotech Stock Research LLC Investment ManagersFinance Founded in 1999, Biotech Stock Research LLC, the parent of Biotech Monthly, is a research firm headquartered in Seattle, Washington. The firm conducts primary and secondary research on developmental-stage biotechnology companies. | Finance |
Angion Biomedica Corp.
 Angion Biomedica Corp. Pharmaceuticals: MajorHealth Technology Angion Biomedica Corp. operates as a biopharmaceutical company. The firm focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 6, 1998 and is headquartered in Newton, MA. | Health Technology |
Alpine Bioventures, GP, LLC
Alpine Bioventures, GP, LLC Investment ManagersFinance Alpine Bioventures, GP, LLC (Alpine Bioventures) is a venture capital firm founded by Mitchell H. Gold in 2013. The firm is headquartered in Seattle, Washington. | Finance |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | Health Technology |
